Drug Profile


Alternative Names: CBT 501; GB 226; PD-1 antibody - Genor Biopharma

Latest Information Update: 06 Mar 2017

Price : $50

At a glance

  • Originator CBT Pharmaceuticals
  • Developer CBT Pharmaceuticals; Genor Biopharma
  • Class Antineoplastics; Monoclonal antibodies; Small molecules
  • Mechanism of Action Immunostimulants; PDCD 1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 23 Feb 2017 Pharmacodynamics data from the preclinical studies released by CBT Pharmaceuticals
  • 21 Feb 2017 CBT Pharmaceuticals plans a phase I trial for Solid tumours (Advanced or Relapsed/Recurrent) in Australia (NCT03053466)
  • 24 Dec 2016 China FDA approves IND application for Genolimzumab in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top